These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3292082)

  • 1. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system.
    Fagnart OC; Sindic CJ; Laterre C
    Clin Chem; 1988 Jul; 34(7):1387-91. PubMed ID: 3292082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
    Hartung HP; Reiners K; Schmidt B; Stoll G; Toyka KV
    Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
    Jury CS; McAllister EJ; MacKie RM
    Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.
    Marchi N; Mazzone P; Fazio V; Mekhail T; Masaryk T; Janigro D
    Cancer; 2008 Mar; 112(6):1313-24. PubMed ID: 18257091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
    Alber B; Hein R; Garbe C; Caroli U; Luppa PB
    Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum neurone-specific enolase concentrations in patients with neurological disorders.
    Cunningham RT; Morrow JI; Johnston CF; Buchanan KD
    Clin Chim Acta; 1994 Oct; 230(2):117-24. PubMed ID: 7834863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle-counting immunoassay of a fetuin-like antigen in serum and cerebrospinal fluid.
    Fagnart OC; Cambiaso CL; Sindic CJ; Masson PL
    Clin Chem; 1985 Nov; 31(11):1820-3. PubMed ID: 2414036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant increase in immunosuppressive acidic protein (IAP) in serum of patients with multiple sclerosis and other inflammatory neurological disorders.
    Tsukamoto T; Seki H; Takase S; Sekizawa T; Nakamura S
    J Neurol Sci; 1986 Oct; 75(3):353-61. PubMed ID: 3772394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroimmunological findings in Guillain Barré syndrome, multiple sclerosis, and idiopathic polyneuropathies.
    Dorta-Contreras A; Silva-Somoza R
    Mol Chem Neuropathol; 1996; 28(1-3):279-84. PubMed ID: 8871970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical relevance of ferritin concentration in the cerebrospinal fluid.
    Sindic CJ; Collet-Cassart D; Cambiaso CL; Masson PL; Laterre EC
    J Neurol Neurosurg Psychiatry; 1981 Apr; 44(4):329-33. PubMed ID: 7241160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T lymphocytes in peripheral blood from patients with neurological diseases.
    Nyland H; Naess A
    Acta Neurol Scand; 1978 Nov; 58(5):272-9. PubMed ID: 310624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum S100--a marker for disease monitoring in metastatic melanoma.
    Henze G; Dummer R; Joller-Jemelka HI; Böni R; Burg G
    Dermatology; 1997; 194(3):208-12. PubMed ID: 9187834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [S100 protein in tumours of the central nervous system].
    Ortiz-Muñoz B; Menéndez-López A; Yayá-Tur R; Arribas-Alpuente L; Maiquez-Richart J; Bordes-Monmeneu M
    Rev Neurol; 2003 Jun 1-15; 36(11):1011-5. PubMed ID: 12808493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum S100 in metastatic malignant melanoma.
    Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
    Eur J Cancer; 1995 Jun; 31A(6):924-8. PubMed ID: 7646923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The glio-fibrillar acid protein in blood serum of patients with brain tumors and neurological diseases of non-tumorous etiology].
    Lyubimova NV; Timofeiev YS; Sushlinskii NE
    Klin Lab Diagn; 2016 Aug; 61(8):466-9. PubMed ID: 30601636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours.
    Gallo P; Piccinno MG; Krzalic L; Tavolato B
    J Neuroimmunol; 1989 Jun; 23(1):41-4. PubMed ID: 2723041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma.
    Schultz ES; Diepgen TL; Von Den Driesch P
    Br J Dermatol; 1998 Mar; 138(3):426-30. PubMed ID: 9580794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.